TOP TEN perturbations for 38533_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38533_s_at
Selected probe(set): 205786_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38533_s_at (205786_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-4.865923Number of Samples:2 / 2
Experimental | expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):4.3460064Number of Samples:2 / 10
Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
Control | normal epidermal Langerhans cell sample |
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):-4.31126Number of Samples:36 / 74
Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
PMA study 2 / mock treated MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.172516Number of Samples:3 / 2
Experimental | PMA study 2 |
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells mock treated. |
expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-4.138956Number of Samples:8 / 2
Experimental | expO ovary cancer study 1 (serous cystadenocarcinoma, NOS; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary serous cystadenocarcinoma (NOS) of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
expO ovary cancer study 1 (endometrioid carcinoma; metastatic) / expO ovary cancer study 1 (dysgerminoma; metastatic)
Relative Expression (log2-ratio):-4.1258593Number of Samples:3 / 2
Experimental | expO ovary cancer study 1 (endometrioid carcinoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary. | |
Control | expO ovary cancer study 1 (dysgerminoma; metastatic) |
Metastatic tumor tissue samples obtained from patients with primary dysgerminoma of the ovary. |
Langerhans cell histiocytosis study 4 / normal tonsillar T-lymphocyte sample
Relative Expression (log2-ratio):4.082945Number of Samples:7 / 4
Experimental | Langerhans cell histiocytosis study 4 |
CD3+ T-lymphocyte samples isolated from peripheral blood of patients with Langerhans cell histiocytosis, prior to chemotherapy treatment. Patient with different clinical status were included in this study (unifocal, single system and multifocal, single system disease). | |
Control | normal tonsillar T-lymphocyte sample |
Normal tonsillar CD3+ T-lymphocytes were isolated from children who undergone elective tonsillectomy. The T-cells were isolated from presumably healthy tissue. |
PMA study 2 (shRNA contr.) / mock treated / transduced MONO-MAC-6 cell sample
Relative Expression (log2-ratio):4.035824Number of Samples:3 / 2
Experimental | PMA study 2 (shRNA contr.) |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then treated with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). ATC code:--- | |
Control | mock treated / transduced MONO-MAC-6 cell sample |
MONO-MAC-6 (MM6) cells were transduced with a control shRNA and then mock treated. |
B-ALL study 1 (hyperdiploid) / normal bone marrow sample
Relative Expression (log2-ratio):-3.9690285Number of Samples:40 / 74
Experimental | B-ALL study 1 (hyperdiploid) |
Bone marrow samples of patients with hyperdiploid B-ALL (hyperdiploid karyotype). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):3.9481077Number of Samples:7 / 3
Experimental | Langerhans cell histiocytosis study 1 |
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity. | |
Control | normal epidermal Langerhans cell sample |
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells. |